A total of 20 patients enrolled in a multicenter phase II dose escalation study of radioimmunotherapy (RIT) using yttrium-90-ibritumomab tiuxetan at two dose levels (22 and 30 MBq/kg) in 10 patients, combined with reduced intensity conditioning (RIC) using fludarabine, melphalan and alemtuzumab followed by allogeneic hematopoietic cell transplantation (HCT) from either matched-related (n ¼ 5) or matched-unrelated donors (n ¼ 15). Postgrafting immunosuppression with cyclosporine was administered. Diagnoses were diffuse large B-cell lymphoma (n ¼ 13), transformed CLL (n ¼ 4), blastic mantle cell lymphoma (n ¼ 2) and follicular lymphoma grade 3 (n ¼ 1). Median age was 51 (range, 29-69) years. All patients were high risk with relapsed/ refractory disease or relapse after preceding autologous HCT. Median follow-up of patients alive was 1115 (range, 1006-1252) days. No directly RIT-related toxicities were observed. The cumulative incidence of non-relapse mortality was 30%. Incidences of grade II-IV acute and chronic GvHD was 45% and 70%, respectively. Kaplan-Meier estimated 3-year OS and EFS were 20% for both dose levels. In conclusion, dose escalation of RIT and combined use with RIC is feasible with no additional toxicity due to dose escalation. This study is registered on http://clinicaltrials.gov as NCT00302757.
INTRODUCTION
Patients with relapsed advanced high-grade non-Hodkin lymphomas (NHL) have a dismal prognosis. However, there are reports of longterm disease free-survival after allogeneic hematopoietic cell transplantation (HCT) in patients with refractory high-grade NHL. 1 Allogeneic HCT offers a number of advantages over standard chemotherapy regimens, including autologous HCT, namely a potent GVL effect, a stem cell source free of neoplastic cells, and a marrow graft without exposure to chemotherapeutic mutagens. These advantages have to compete with the higher TRM of up to 40% and the complications of GvHD. [2] [3] [4] Most patients with advanced relapsed high-grade NHL have received multiple preceding chemoand radiotherapy cycles often including autologous HCT. They can therefore often not tolerate intensive myeloablative conditionings. Reduced intensity conditioning (RIC) regimens have been developed to overcome these limitations and to allow allogeneic HCT in comorbid or elderly patients with contraindications for myeloablative HCT. 5 Owing to the low anti-lymphoma efficacy of RIC, the burden of anti-lymphoma activity is shifted to the allogeneic graft. Promising data for the treatment of patients with advanced high-grade NHL have been reported using RIC containing fludarabine, melphalan and alemtuzumab. 6 A new strategy to increase the anti-lymphoma activity of RIC without increasing the toxicity might be the additional use of radioimmunotherapy (RIT). The radiolabeled anti-CD20 antibody (yttrium-90 ( 90 Y) ibritumomab tiuxetan, Zevalin, Bayer Health Care, Leverkusen, Germany) has been shown to have potent activity in patients with NHL. [7] [8] [9] [10] Dose-limiting toxicity of RIT is hematological toxicity. The use of RIT in the context of allogeneic HCT may therefore allow dose escalation of RIT. In this phase II study, we prospectively evaluated the use of dose-escalated targeted radiotherapy with 90 Patients with advanced CD20 þ disease relapsed after 42 preceding chemotherapy regimens including rituximab or with relapse after autologous HCT could be enrolled. Further inclusion criteria were age 418, o70 years, Karnofsky score 460%, availability of a HLA-compatible (9-10/10 match)-related or -unrelated donor (URD) and disease stage at inclusion either CR, PR or stable disease.
Exclusion criteria were rapidly progressive disease, o3 months after preceding HCT, central nervous system involvement with disease, uncontrolled fungal infections, liver function abnormalities with bilirubin 42 mg/dL and transaminases 42 Â upper limit of normal, chronic active viral hepatitis, ejection fraction o40%, patients with 4grade II hypertension by the Common Toxicity Criteria, creatinine clearance o50 mL/min, respiratory failure necessitating supplemental oxygen or diffusing capacity for carbon monoxide o30%, allergy against murine antibodies, HIV infection, pregnancy or breast feeding, no adequate contraceptive method, pleural effusion or ascites.
HLA typing, matching, stem cell mobilization and collection
Patients and their donors were tested for HLA-A, HLA-B, HLA-C, HLA-DRB1 and HLA-DQB1 by high-resolution molecular typing methods. A single allele/antigen disparity was allowed. G-CSF mobilized PBSC grafts from HLA-compatible (9-10/10) MRD or URD were used.
Dosimetry, conditioning regimen and transplantation
All patients enrolled received dosimetry using 111 In-ibritumomab tiuxetan on day À 21 to meet radiation safety requirements of this approach according to the German federal regulations. For dosimetry, sequential whole-body scans in anterior and posterior projections were performed using a gamma camera immediately after 111 In-ibritumomab tiuxetan administration and repeated 3 h post infection, on day 1, day 3 or 4 and on day 6. Dose estimation of organs receiving potentially dose-limiting radiation doses such as the liver, kidney, red marrow, spleen and lung were performed.
Before RIT, the patients received two infusions of 250 mg/m 2 rituximab. The first rituximab infusion was given in combination with 185 MBq (5 mCi) Monitoring of patients for engraftment, chimerism, disease, toxicity and donor lymphocyte infusions (DLIs) Hematopoietic donor cell chimerism was monitored every 4 weeks in all patients using microsatellite markers as described. 11 Engraftment was assessed by peripheral blood cell counts. Engraftment was defined as the first day on which the absolute neutrophil count was consistently over 500 absolute neutrophil count/mL. Platelet engraftment was defined as the first day with consistently 420 000 platelets/mL.
For disease staging and to assess disease response, all patients received computed tomography scans or positron emission tomography-computed tomography scans within 4 weeks of start of conditioning and on day þ 30, þ 100 and after 1 year or if clinically indicated. Response was assessed using criteria of the international working group. 12 GvHD was assessed and graded as described. 13 Toxicities were scored according to the National Cancer Institute Common Toxicity Criteria (Version 3.0). Patients were eligible to receive additional DLIs in case of relapse or progression of underlying disease.
Statistical analysis
The primary objectives of this study were feasibility and treatment-related toxicity of the combined use of dose-escalated RIT and RIC for allogeneic HCT. Disease response, survival and GvHD were evaluated as secondary objectives. For statistical analysis GraphPad Prism (GraphPad Software Inc., La Jolla, CA, USA) and R (R Foundation for Statistical Computing, Vienna, Austria) 14 biostatistical software was used. Actuarial curves were estimated according to the Kaplan-Meier method, the log-rank test was used for the comparison of Kaplan-Meier estimates. The OS was measured as the number of days from transplantation to death from any cause. Patients who were still alive at follow-up were censored at the last follow-up date. Time to non-relapse mortality (NRM) included only deceased patients who died without preceding relapse. EFS was calculated as the number of days from HCT until relapse/progression/death. Patients without evidence for relapse/progression were censored at the last follow-up date or date of death. Cumulative incidence curves for NRM and relapse were adjusted for competing risks using R as described. 15 All P-values are two-sided.
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In Figure 1 . Study protocol.
RESULTS

Patients
A total of 20 patients with advanced high-grade NHL either with relapsed/refractory disease (n ¼ 11) or relapse after preceding autologous HCT (n ¼ 9) have been enrolled in the study (Table 1) . Diagnoses were DLBCL (n ¼ 13), t-CLL; n ¼ 4), blastic-mantle cell lymphoma (n ¼ 2) and FL grade 3 (n ¼ 1 Transplantation details All patients received HCT with G-CSF mobilized PBSC grafts. The median CD34 þ cell dose was 5.6 Â 10 6 (range, 2.5-18.5 Â 10 6 ) CD34 þ cells/kg. HLA-compatible (9-10/10) grafts were either from MRD (n ¼ 5) or URD (n ¼ 15). Among the 15 patients transplanted from URD, in 2 patients one antigen mismatches in HLA-C, in 5 patients antigen or allelic mismatches in either HLA-A (n ¼ 1), -B (n ¼ 3) or -DQ (n ¼ 1) were present.
Engraftment
The median time to 4500 absolute neutrophil count/mL was 15 (range, 9-32) days, and to 420 000 platelets/mL was 11 (range, 9-56) days. Median absolute neutrophile count nadir was 0 (range, 0-100) cells/mL, median nadir of platelets was 8000 (range, 2000-20 000) cells/mL. All patients engrafted with full donor chimerism by day 28 after HCT. We observed no cases of graft rejection. An absolute lymphocyte count of 4500/mL could be documented in 11 patients within 500 days after HCT.
Dosimetry
In all, 90% of the energy of the b-emitter 90 Y is absorbed within a radius of 5.3 mm, 17 which enables administration of 90 Y-ibritumomab tiuxetan in an outpatient setting. Dosimetry data were available in 18 patients. Dosimetry was done for reasons of radiation safety and not used to calculate administered radiation dose, which was weight based. In two patients dosimetry was not evaluable due to technical failure. Supplementary Table 3 gives details of the administered absolute and organ doses determined to the liver, kidney, red marrow, spleen and lung.
Organ toxicity The combination of RIT with RIC seemed not to increase the toxicity in comparison with the previous experience in patients conditioned with fludarabine/melphalan/alemtuzumab alone. 6 In particular, we observed no cases of veno-occlusive disease, no increased rate of mucositis or nephrotoxicity. Supplementary Table 4 summarizes the maximum organ toxicity observed up to day þ 180 according to the Common Toxicity Criteria V3.0. Toxicity was within the range expected after allogeneic HCT using RIC and mainly grade 2-3 excluding expected hematological grade 4 toxicity.
Graft-versus-host disease The observed incidence of grade II-IV aGvHD was 45% with maximum grade II in eight patients (gut ¼ 3, skin ¼ 5, 40%) and grade IV in one patient (gut and liver, 5%). Chronic GvHD occurred in 14 patients (70%), which was extensive in 12 patients (60%).
Non-relapse mortality Six patients died due to NRM. Causes of deaths were infections (n ¼ 3), GvHD (n ¼ 2) and suspected air embolism (n ¼ 1; Supplementary Table 5 ). Cumulative incidence estimate of NRM was 0% up to day þ 100 and 30% after 3 years (Figure 2 ). Disease response, relapse, event-free and OS Four patients (DLBCL ¼ 3 and transformed CLL ¼ 1) were in CR at the time of HCT. One of these patients relapsed after HCT. Two of these patients (DLBCL ¼ 2) died due to NRM. Of the 15 patients in PR at the time of HCT, 4 converted to CR, 6 remained in PR, 1 had stable disease and 4 patients progressed until day þ 100. One patient with stable disease at the time of HCT progressed before day þ 30. At last follow-up 02/2011, 4/20 are alive and in CR. Among the three patients with bulky disease, one patient progressed, one patient achieved PR and one patient CR. Table 2 gives details on outcome by disease histology. A total of 10 patients relapsed/progressed, resulting in a cumulative incidence estimate of relapse of 50% (Figure 2 ). Median followup of patients alive was 1115 (range, 1006-1252) days. The Kaplan-Meier estimated 3-year OS and EFS was 20% for both dose levels ( Figure 3) . Kaplan-Meier estimated 3-year OS after HCT from MRD or URD was 20%. Kaplan-Meier estimated 3-year OS and EFS Escalated radioimmunotherapy for allogeneic HCT WA Bethge et al was 0% for blastic mantle cell lymphoma and FL grade 3, 15% for DLBCL and 50% for t-CLL (Supplementary Figure 4) .
Donor lymphocyte infusions
Four patients received DLI after allogeneic HCT, three for progressive disease and one for treatment refractory viral infection. All patients consecutively developed GvHD. All of these patients died. Causes of death were infection ¼ 1, GvHD ¼ 1 and relapse ¼ 2.
DISCUSSION
RIT using 90 Y radiolabeled monoclonal anti-CD20 antibodies has emerged as a promising new therapeutic strategy for the treatment CD20 of positive lymphoma patients. A number of studies have shown high response rate and long-term remission induction even in patients with advanced disease. Multiple trials have shown that single-agent 90 Y-ibritumomab tiuxetan can induce impressive disease responses with overall response rates of 73-83% and CR rates of 15-51% leading to long-term remissions in patients with refractory indolent and high-grade NHL. [7] [8] [9] [10] [18] [19] [20] For patients with advanced DLBCL ineligible for autologous HCT response rates of up to 53% and CR rates up to 39.5% of patients have been reported. 21 Given that the doselimiting toxicity of 90 Y-ibritumomab tiuxetan is hematological toxicity, 22 radiolabeled antibodies are potentially ideal agents to be used in the context of allogeneic HCT as the graft reverses the dose-limiting toxicity and may allow further dose escalation of RIT. Combined use of RIT with RIC may enhance the otherwise limited antilymphoma activity of RIC. The vast majorities of studies using RIT in the context of HCT have been performed in autologous HCT proving that RIT does not hamper engraftment if an adequate time interval between RIT administration and stem cell transfer is assured. A number of studies combined standard dose 90 Y-ibritumomab tiuxetan or 131 I-tositumobmab with high-dose conditioning using BEAM followed by autologous HCT with moderate toxicity and promising disease response. [23] [24] [25] [26] Dose escalation studies of RIT with 90 Y-ibritumomab tiuxetan as a single agent together with autologous HCT were also performed showing an acceptable safety profile up to a dose of 45 MBq/kg. 27, 28 In allogeneic HCT, so far only standard dose (15 MBq/kg (0.4 mCi/kg)) 90 Y-ibritumomab tiuxetan has been used as part of the conditioning. Shimoni et al. 29 reported 12 patients with lowand high-grade NHL treated with RIT using 90 Y-ibritumomab tiuxetan followed by RIC with fludarabine/BU/melphalan. Fietz et al. 30 reported two additional patients combining 90 Y-ibritumomab tiuxetan with RIC using fludarabine/cyclophosphamide. Previously, we reported a cohort of 40 patients treated with 90 Y-ibritumomab tiuxetan at a dose of 15 MBq/kg (0.4 mCi/kg) followed by RIC with fludarabine/2 Gy TBI and allogeneic HCT from MUD or MRD. 31 We observed moderate toxicity of this approach with main toxicities related to RIC and allogeneic HCT but not attributable specifically to RIT. Promising disease responses and long-term outcomes in particular in patients with FL and CLL have been observed. However, NRM was 45% at 2 years, most probably related to the high-risk patient cohort treated. Recently, Gopal et al. 32 reported a similar approach using the same RIC and reported a NRM of only 16%, which may have been the result of a different patient selection.
The study reported here is the largest prospective trial of doseescalated RIT in the context of RIC for allogeneic HCT. This study demonstrates the feasibility and safety of the combined use of dose-escalated RIT with RIC before allogeneic HCT in patients with advanced NHL using up to the double standard dose of RIT. Dosimetry performed in the patients confirmed radiation doses to be above the range previously reported in trials of standard dose 90 Y-ibritumomab tiuxetan and similar to previous studies of doseescalated RIT in the context of autologous HCT. 33, 34 No additional toxicities attributable to RIT compared with toxicities reported previously with this regimen without RIT were observed. 6 Toxicity observed within the first 180 days after transplantation was moderate with mainly Common Toxicity Criteria grade 2-3 toxicities.
In spite of the moderate acute toxicity of the regimen, the cumulative incidence of NRM was 30% in our study. This relatively high NRM was not entirely unexpected given an average EBMT-risk score of 6 in our patient cohort, which is associated with a NRM of B40% for RIC-HCT. 16 The high EBMT score reflects the age of the patients, the advanced stage of their disease and the predominant use of URDs. Furthermore, in a cohort of patients with high-grade NHL using the same RIC but without additional RIT, Morris et al. 6 reported an estimated 3-year NRM of 38%. However, Gopal et al. 32 reported in their study of standard dose RIT using 90 Y-ibritumomab tiuxetan combined with a conditioning with fludarabine/2 Gy TBI in a similar high-risk cohort of patients an incidence of NRM of only 16%. Therefore, the relatively high NRM in our study might be also related to the RIC regimen used including alemtuzumab as GvHD prophylaxis. The NRM in our study is attributable both to the high incidence of lethal infections and chronic GvHD. Any impact of dose-escalated RIT on the incidence of infections and GvHD is hard to exclude without a control group, but given the fact that most of NRM occurred way beyond day þ 100 a negative impact of RIT on NRM seems very unlikely.
The high incidence of infections might be related to the extensive preceding therapies including nine patients with prior autologous HCTs, the use of alemtuzumab as agent for GvHD prevention within the conditioning and the delayed lymphocyte recovery observed after HCT. Despite the use of alemtuzumab, incidence of acute and chronic GvHD was high with 45% and 75%, respectively. Owing to the high-risk disease (only four patients in CR) or relapse early taper of immunosuppression and DLI was used to induce a GVL effect. In addition, 15/20 patients received grafts from URD and 7 from a mismatched donor.
This trial was designed to evaluate feasibility and toxicity, therefore disease response and survival should be interpreted very cautiously. The cumulative incidence of relapse was high with 50%. First, this may be related to the fact that only 4/20 patients were in CR prior allogeneic HCT. Taking this into account, our results for OS and EFS at 3 years for patients with DLBCL and transformed CLL seem comparable to data published so far using different RIC regimens. 35, 36 Morris et al. 6 reported 34% OS and PFS at 3 years using fludarabine/melphalan in high-grade NHL. Second, this may be related to the use of in vivo T-cell depletion with alemtuzumab for GvHD prophylaxis in our RIC regimen. In a recent retrospective analysis Soiffer et al. 37 could show that the use of in vivo T-cell depletion in the context of RIC leads to a significant increase in the rate of relapse. Furthermore, disease stage and pace of relapse in the patient with aggressive NHL as treated within this study precluded a meaningful strategy of preemptive additional DLI after in vivo T-cell depletion as propagated for FL by Thomson et al. 38 This may also explain why the use of additional dose-escalated RIT combined with RIC in our case did not lead to a lower incidence of relapse compared with less intense RIC regimens without or with RIT as reported by Gopal et al. and Rezvani et al. 32, 39 For future studies, we therefore would suggest omitting additional in vivo T-cell depletion using alemtuzumab.
In summary, our study demonstrated the safety and feasibility of a combination of RIT with dose-escalated 90 Y-ibritumomab tiuxetan and RIC for allogeneic HCT. This study sets the stage for future randomized studies to evaluate the additional impact of dose-escalated RIT in the conditioning regimen for allogeneic HCT.
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